Data Matrix Date Matrix

Data MATRIX provides data processing and biostatistics services in clinical research and develops cloud-based software for clinical research. The team has conducted more than 100 projects for major pharmaceutical and biotechnology companies and CROs. Data MATRIX products include applications such as EDC, IWRS and Pharmacovigilance, as well as CTMS, DDP, ERP applications in the process of development . The company is a member of the professional societies ACDM, SCDM and a resident of the Skolkovo Foundation Biomed Cluster.

History

2019: Agreement with Seoul CRO to implement Data Matrix solutions in South Korea

On April 24, the St. Petersburg company Data Matrix announced the signing of a cooperation agreement with Seoul CRO, one of the leading contract research organizations in South Korea. This document launched the introduction of IT developments for the Korean pharmaceutical industry. Read more here.

2018: Data Matrix localizes Korea solutions with Seoul CRO

Software developer and data services provider Data Matrix and Korean company Seoul CRO on July 10, 2018 announced the start of joint work aimed at introducing IT products and cloud services for clinical research to the Korean market.

The companies plan to localize a number of software solutions for the features of the Korean pharmaceutical market. Acting as a partner, Seoul CRO will promote the implementation of IT products and services.

Data Matrix Executive Director Ivan Dobromyslov sees great potential in cooperation, which is largely due to the rapidly growing Asian market and the shortage of available software solutions for clinical research, as well as the experience of preparing data for submission to the EMA and FDA regulators.

It is expected that the collaboration will expand the geography of Data Matrix's presence abroad: the company already has representative offices in the USA and Germany.

2017: Data MATRIX becomes a member of CDISC international community

Even though Data MATRIX became a member in CDISC 2017, the team strictly adhered to the organization's standards for data processing, statistical analysis and preparation of medical records from the company's first day in office. This approach not only ensures the high quality of data from Data MATRIX projects, which are successfully accepted by Russian and foreign regulatory bodies. The introduction of standards optimizes the work of the company's structural divisions at many stages and reduces resources at the stage of launching a clinical trial by 70-90% and by 60% within the framework of the entire project.

For the Data MATRIX command, it is especially important that in CDISC projects, it is possible to track the entire path of data from obtaining it to output based on it. This allows you to exclude forgery, minimize the risk of errors, which makes all actions regarding data during the study standard and transparent, including for regulatory authorities. Open data, its maximum transparency for industry participants in recent years has become the main trend in the development of the industry. This trend finds serious support in the face of the FDA and EMA.

2016: The venture capital fund Primer Capital and IIDF will invest Data MATRIX 160 million rubles

The leading investor in the deal will be the Internet Initiatives Development Fund (IIDF), which plans to invest 150 million rubles in Data MATRIX, and the project also raised 10 million rubles from the Primer Capital venture capital fund .

The Data MATRIX project is the first specialized software in Russia for organizing and managing a clinical trial in accordance with world standards and requirements.

Dobromyslov Ivan, CEO of Data MATRIX: "Our product solves the difficult tasks of patient randomization, drug supply management, data collection and drug safety monitoring. In the future, the new modules will allow you to track the financial part of the study, carry out quality control, project management and much more. "

The investment consultant was the Investment Service of the Skolkovo Foundation, which participated in preparing the company to attract investments in the current round. Since 2014, Data MATRIX has been a resident of the Foundation's Biomed Cluster. Legal support of the transaction was carried out by the Skolkovo CIS.

The investments received will be used to develop the project and enter foreign markets.

"Every year, the number of medical drug developments in the world is growing by 5%. In recent years, the share of research on cancer drugs has seriously increased, and this requires complicating the design of studies and increasing their cost - about 20% of trials in the United States already require the use of adaptive design. We see interest on the part of the market in this decision - the project team is already working with large companies and showing successful results, "comments Sergei Negodyaev, investment portfolio manager at the IIDF.